Virpax Pharmaceuticals, Inc. (VRPX) has disclosed a new risk, in the Corporate Activity and Growth category.
Virpax Pharmaceuticals, Inc. faces a substantial business risk due to the financial obligations imposed by the Settlement Agreement. The stipulated cash and royalty payments to the Plaintiffs, along with potential compensations to the former CEO, could severely constrain the company’s resources. This financial strain might force Virpax to halt the development of some, if not all, product candidates if profitability is deemed unattainable. Moreover, these payments could adversely affect the company’s revenue projections and impede prospective partnerships and acquisitions critical for its growth.
The average VRPX stock price target is $20.00, implying 415.46% upside potential.
To learn more about Virpax Pharmaceuticals, Inc.’s risk factors, click here.
